Abstract:Cancer encompasses various elements occurring at the cellular and genetic levels, necessitating an immunotherapy capable of efficiently addressing both aspects. T cells can combat cancer cells by specifically recognizing antigens on them. This innate capability of T cells has been used to develop cellular immunotherapies, but most of them can only target antigens through major histocompatibility complexes (MHCs). New gene-editing techniques such as clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein 9 (CRISPR-cas9) can precisely edit the DNA sequences. CRISPR-cas9 has made it possible to generate genetically engineered chimeric antigen receptors (CARs) that can overcome the problems associated with old immunotherapies. In chimeric antigen receptor T (CAR-T) cell therapy, the patient's T cells are isolated and genetically modified to exhibit synthetic CAR(s). CAR-T cell treatment has shown remarkably positive clinical outcomes in cancers of various types. Nevertheless, there are various challenges that reduce CAR-T effectiveness in solid tumors. It is required to address these challenges in order to make CAR-T cell therapy a better and safer option. Combining CAR-T treatment with other immunotherapies that target multiple antigens has shown positive outcomes. Moreover, recently generated Boolean logic-gated advanced CARs along with artificial intelligence has expanded its potential to treat solid tumors in addition to blood cancers. This review aims to describe the structure, types, and various methods used to develop CAR-T cells. The clinical applications of CAR-T cells in hematological malignancies and solid tumours have been described in detail. In addition, this discussion has addressed the limitations associated with CAR-T cells, explored potential strategies to mitigate CAR-T-related toxicities, and delved into future perspectives.

Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Potentials, Limitations, and Future Prospects

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

[Advances in Immunotherapy of Hematological Malignancies by Using Chimeric Antigen Receptor-Modified Lymphocytes].

Chimeric Antigen Receptor for Adoptive Immunotherapy of Cancer: Latest Research and Future Prospects.

Research Advances in Chimeric Antigen Receptor-Modified T-cell Therapy (Review)

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Chimeric Antigen Receptor T-cell Therapy Beyond Cancer: Current Practice and Future Prospects.

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors

Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy development

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

Chimeric antigen receptor-immune cells against solid tumors: Structures, mechanisms, recent advances, and future developments

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

CAR T-Cell Therapy: The Next Frontier for Cancer Immunotherapy